Search This Blog

Wednesday, November 6, 2019

Esperion Therapeutics EPS misses by $0.57, misses on revenue

Esperion Therapeutics (NASDAQ:ESPR): Q3 GAAP EPS of -$2.52 misses by $0.57.
Revenue of $0.98M misses by $0.01M.
Cash and equivalents of $211.98M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)